Cure8 research brief
Researchers are exploring microbiome-derived molecules as targeted, locally acting therapies for ulcerative colitis that might avoid systemic immunosuppression. EB1010 showed anti-inflammatory activity and mucosal-protective effects in laboratory and animal models and was well tolerated in preliminary toxicology.
Researchers studying microbiome therapeutics, translational IBD scientists, clinician-investigators, and patients interested in emerging microbiome-derived treatment approaches for ulcerative colitis.
This paper reports EB1010, a 28-residue peptide derived from a Christensenellaceae bacterial protein, as a candidate anti-inflammatory therapeutic for ulcerative colitis.
In vitro and ex vivo assays showed reduced proinflammatory mediator secretion, inhibition of NF-κB signaling, and preservation of barrier integrity; oral dosing reduced inflammation in rat and mouse chemical colitis models.
Pharmacokinetic and transport data suggest minimal systemic absorption and a local intestinal mode of action; a 4-week rat toxicology study showed no adverse effects at tested doses.
The findings are preclinical (cell, ex vivo human tissue, and animal models) and describe a microbiome-derived peptide with potential to modulate innate immune signaling (possible interference with TLR4) and promote mucosal healing. This work focuses on discovery and early-stage evaluation rather than clinical efficacy in humans.
Next steps would typically include additional safety/toxicology, dose-finding, and well-controlled human trials before any treatment claim can be applied to people with UC.
This is a full-text preclinical research article reporting cell, ex vivo human tissue, and animal model data. It does not report human clinical trial results. The peptide showed minimal plasma exposure in animal PK studies, suggesting a local intestinal effect, but human safety and efficacy remain untested.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Antonietta Cultrone, Laurent Chene, Francesco Strozzi, Christophe Bonny are the inventors of a patent application protecting EB1010 (WO 2023006774). The other authors have no conflicts of interest to declare aside from the fact that several of the authors are employees of private companies.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study suggests a new host-directed mechanism that helps a common beneficial gut bacterium (Faecalibacterium prausnitzii) colonize and protect the gut lining, and identifies heparan sulfate as a potential way to...
Researchers are exploring plant-derived polysaccharides as potential therapies that might reduce inflammation and protect the intestinal barrier. For people with UC, therapies that reduce pyroptosis and restore...
The study identifies a plant extract that reduced colitis-like injury in mice and altered gut microbes and intestinal barrier markers, which could inform future preclinical work. For people with IBD, this is early-stage...
